BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30069738)

  • 1. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    Jäger T; Neureiter D; Fallaha M; Schredl P; Kiesslich T; Urbas R; Klieser E; Holzinger J; Sedlmayer F; Emmanuel K; Dinnewitzer A
    Strahlenther Onkol; 2018 Nov; 194(11):991-1006. PubMed ID: 30069738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy.
    Rogers AC; Gibbons D; Hanly AM; Hyland JM; O'Connell PR; Winter DC; Sheahan K
    Mod Pathol; 2014 Jan; 27(1):156-62. PubMed ID: 23887296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
    D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
    Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
    Jung JH; An HJ; Kim HJ; Lee J; Lee KM; Kim SH; Cho HM; Shim BY
    Korean J Intern Med; 2016 Jan; 31(1):134-44. PubMed ID: 26767867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of tumor budding in patients who had surgery for rectal cancer with and without neoadjuvant therapy.
    Şirin AH; Sökmen S; Ünlü SM; Ellidokuz H; Sarioğlu S
    Tech Coloproctol; 2019 Apr; 23(4):333-342. PubMed ID: 30900039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
    Trotsyuk I; Sparschuh H; Müller AJ; Neumann K; Kruschewski M; Horst D; Elezkurtaj S
    BMC Cancer; 2019 Nov; 19(1):1033. PubMed ID: 31675950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
    Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
    World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
    Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer.
    Sada YH; Tran Cao HS; Chang GJ; Artinyan A; Musher BL; Smaglo BG; Massarweh NN
    J Surg Res; 2018 Jun; 226():15-23. PubMed ID: 29661280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
    Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
    Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital.
    Yeung WW; Ma BB; Lee JF; Ng SS; Cheung MH; Ho WM; Tsang MW; Chu S; Lam DC; Mo FK
    Hong Kong Med J; 2016 Dec; 22(6):546-55. PubMed ID: 27795447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy.
    Park IJ; Yu CS; Lim SB; Yoon YS; Kim CW; Kim TW; Kim JH; Kim JC
    World J Gastroenterol; 2015 Mar; 21(11):3274-81. PubMed ID: 25805934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.